Literature DB >> 24698008

[Susceptibility to azithromycin and other antibiotics in recent isolates of Salmonella, Shigella and Yersinia].

Angeles Martín-Pozo1, David M Arana1, Miriam Fuentes1, Juan-Ignacio Alós2.   

Abstract

INTRODUCTION: Azithromycin represents an alternative option to treat bacterial diarrhea when the antibiotic therapy is indicated. Little is known regarding the susceptibility to azithromycin in enteropathogens in Spain.
METHODS: The MICs of azithromycin were determined by E-test against Salmonella non-typhi (SNT), Shigella and Yersinia isolates collected over the last three years (2010-2012). In addition, the susceptibility to other antibiotics usually used to treat gastrointestinal diseases was determined in these isolates by using a microdilution method.
RESULTS: A total of 139 strains of SNT, Shigella and Yersinia were studied. All of them, except one strain, had a MIC≤16mg/L of azithromycin. In the adult population, 14.7% and 40.6% of SNT and Shigella isolates, respectively, were resistant to at least 2 of following antibiotics: amoxicillin, trimethoprim-sulfamethoxazole and ciprofloxacin. In the pediatric population, 10% of SNT clinical isolates and 28.6% (2/7) of Shigella isolates were resistant to amoxicillin and trimethoprim-sulfamethoxazole.
CONCLUSIONS: In our experience, azithromycin would be a useful antibiotic alternative to treat bacterial diarrhea.
Copyright © 2013 Elsevier España, S.L. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Azithromycin; Azitromicina; Bacterial diarrhea; Diarrea bacteriana; Salmonella; Shigella

Mesh:

Substances:

Year:  2014        PMID: 24698008     DOI: 10.1016/j.eimc.2014.02.010

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  1 in total

1.  Thirty years of human infections caused by Yersinia enterocolitica in northern Spain: 1985-2014.

Authors:  J M Marimon; R Figueroa; P Idigoras; M Gomariz; M Alkorta; G Cilla; E Pérez-Trallero
Journal:  Epidemiol Infect       Date:  2017-06-05       Impact factor: 4.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.